Atrium Therapeutics, Inc.
RNA
$13.19
$0.413.21%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1,148.25% | -71.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1,148.25% | -71.11% | |||
| Cost of Revenue | 71.02% | 90.03% | |||
| Gross Profit | 286.31% | -195.40% | |||
| SG&A Expenses | 870.21% | 819.24% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 309.03% | 224.82% | |||
| Operating Income | -131.88% | -365.56% | |||
| Income Before Tax | -123.29% | -365.86% | |||
| Income Tax Expenses | -- | -99.35% | |||
| Earnings from Continuing Operations | -123.29% | -153.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -123.29% | -153.09% | |||
| EBIT | -131.88% | -365.56% | |||
| EBITDA | -131.50% | -367.95% | |||
| EPS Basic | -123.28% | -- | |||
| Normalized Basic EPS | -123.25% | -- | |||
| EPS Diluted | -123.28% | -- | |||
| Normalized Diluted EPS | -123.25% | -- | |||
| Average Basic Shares Outstanding | 0.00% | -- | |||
| Average Diluted Shares Outstanding | 0.00% | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||